Lidocaine as an anti-arrhythmic drug : Are there any indications left?
© 2023 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics..
Lidocaine is classified as a class Ib anti-arrhythmic that blocks voltage- and pH-dependent sodium channels. It exhibits well investigated anti-arrhythmic effects and has been the anti-arrhythmic of choice for the treatment of ventricular arrhythmias for several decades. Lidocaine binds primarily to inactivated sodium channels, decreases the action potential duration, and increases the refractory period. It increases the ventricular fibrillatory threshold and can interrupt life-threatening tachycardias caused by re-entrant mechanisms, especially in ischemic tissue. Its use was pushed into the background in the era of amiodarone and modern electric device therapy. Recently, lidocaine has come back into focus for the treatment of acute sustained ventricular tachyarrhythmias. In this brief overview, we review the clinical pharmacology including possible side effects, the historical course, possible indications, and current Guideline recommendations for the use of lidocaine.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Clinical and translational science - 16(2023), 12 vom: 01. Dez., Seite 2429-2437 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Güler, Sati [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
98PI200987 |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 17.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/cts.13650 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362778183 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362778183 | ||
| 003 | DE-627 | ||
| 005 | 20240418232310.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cts.13650 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1379.xml |
| 035 | |a (DE-627)NLM362778183 | ||
| 035 | |a (NLM)37781966 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Güler, Sati |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Lidocaine as an anti-arrhythmic drug |b Are there any indications left? |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 17.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. | ||
| 520 | |a Lidocaine is classified as a class Ib anti-arrhythmic that blocks voltage- and pH-dependent sodium channels. It exhibits well investigated anti-arrhythmic effects and has been the anti-arrhythmic of choice for the treatment of ventricular arrhythmias for several decades. Lidocaine binds primarily to inactivated sodium channels, decreases the action potential duration, and increases the refractory period. It increases the ventricular fibrillatory threshold and can interrupt life-threatening tachycardias caused by re-entrant mechanisms, especially in ischemic tissue. Its use was pushed into the background in the era of amiodarone and modern electric device therapy. Recently, lidocaine has come back into focus for the treatment of acute sustained ventricular tachyarrhythmias. In this brief overview, we review the clinical pharmacology including possible side effects, the historical course, possible indications, and current Guideline recommendations for the use of lidocaine | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Lidocaine |2 NLM | |
| 650 | 7 | |a 98PI200987 |2 NLM | |
| 650 | 7 | |a Anti-Arrhythmia Agents |2 NLM | |
| 650 | 7 | |a Amiodarone |2 NLM | |
| 650 | 7 | |a N3RQ532IUT |2 NLM | |
| 650 | 7 | |a Sodium Channels |2 NLM | |
| 700 | 1 | |a Könemann, Hilke |e verfasserin |4 aut | |
| 700 | 1 | |a Wolfes, Julian |e verfasserin |4 aut | |
| 700 | 1 | |a Güner, Fatih |e verfasserin |4 aut | |
| 700 | 1 | |a Ellermann, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Rath, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Frommeyer, Gerrit |e verfasserin |4 aut | |
| 700 | 1 | |a Lange, Philipp Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Köbe, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Reinke, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Eckardt, Lars |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical and translational science |d 2008 |g 16(2023), 12 vom: 01. Dez., Seite 2429-2437 |w (DE-627)NLM186388268 |x 1752-8062 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2023 |g number:12 |g day:01 |g month:12 |g pages:2429-2437 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cts.13650 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2023 |e 12 |b 01 |c 12 |h 2429-2437 | ||